Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors
Rhea-AI Summary
Edesa Biotech (Nasdaq: EDSA) entered a securities purchase agreement for a PIPE financing expected to raise approximately $3.5 million in gross proceeds. The deal covers 729,241 common shares at $4.69 per share for investors and $5.21 for the CEO.
The private placement, led by the CEO and healthcare-focused investors, is expected to close on or about June 15, 2026, subject to customary conditions. Edesa plans to use net proceeds to advance its vitiligo program, its drug candidate paridiprubart, and for working capital and general corporate purposes. The company agreed to file an SEC resale registration statement within 45 days of closing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- PIPE financing expected to raise approximately $3.5 million in gross proceeds
- Issuance of 729,241 common shares at defined prices provides new equity capital
- Net proceeds earmarked for vitiligo program, paridiprubart, and working capital
- Participation by CEO and healthcare-focused investors, with CEO paying $5.21 per share
Negative
- Sale of 729,241 new common shares increases share count and dilutes existing holders
News Market Reaction – EDSA
On the day this news was published, EDSA gained 8.45%, reflecting a notable positive market reaction. Argus tracked a peak move of +14.0% during that session. Argus tracked a trough of -8.9% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $4M to the company's valuation, bringing the market cap to $55.66M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Private placement Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 13 | Private placement financing | Positive | +74.7% | Announced $15M private placement to fund EB06 Phase 2 vitiligo study. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Limited tag-specific history: the prior private placement coincided with a strong +74.73% move.
Over the past year, Edesa’s key financing event was a $15.0M private placement on Feb 13, 2025, led by institutional investors and insiders, to fund EB06’s Phase 2 vitiligo study through fiscal 2026. That deal included both preferred and common shares and triggered a +74.73% one-day move. Today’s smaller $3.5M PIPE, also supporting vitiligo and paridiprubart development, continues this pattern of targeted capital raises tied to pipeline advancement.
Key Terms
private placement financial
pipe financing financial
section 4(a)(2) regulatory
regulation d regulatory
accredited investors financial
prospectus exemptions regulatory
registration statement regulatory
form 8-k regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately
In the PIPE, the Company is selling an aggregate of 729,241 common shares, at a purchase price of
Edesa currently expects to use the net proceeds from the PIPE to fund the continued advancement of the Company’s vitiligo program, the Company’s drug candidate, paridiprubart, and for working capital and general corporate purposes.
The securities described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act"), and Regulation D promulgated thereunder and have not been and will not be registered under the Act, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The securities described above may be offered to "accredited investors" within the meaning of the Canadian National Instrument 45-106 - Prospectus Exemptions. Securities issued in Canada may be subject to applicable Canadian hold periods imposed under applicable securities legislation. Edesa has agreed to file a registration statement with the U.S. Securities and Exchange Commission (“SEC”) registering the resale of the common shares within 45 days of the closing.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. The Company plans to file a Current Report on Form 8-K with the SEC with additional details of the PIPE. In addition, in Canada, a material change report with respect to the PIPE is expected to be filed less than 21 days before the expected closing date of the PIPE, which is reasonable and necessary in the circumstances for the Company to take advantage of available financing opportunities.
About Edesa Biotech, Inc.
Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Its clinical pipeline is focused on two therapeutic areas: Medical Dermatology and Respiratory. In Medical Dermatology, Edesa is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (
Edesa Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions, including statements related to Edesa’s ability to complete the PIPE financing, the anticipated proceeds to be received in the PIPE financing, the expected timing of the closing of the PIPE financing and the expected use of the proceeds from the PIPE financing. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: market and other conditions, those relating to the anticipated use of proceeds, the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises. Many of these factors that will determine actual results are beyond the Company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.
Contact:
Gary Koppenjan
Edesa Biotech, Inc.
investors@edesabiotech.com
